The Evidence Behind Flore
Flore's formulation intelligence is grounded in real-world data from our own cohorts and in published, peer-reviewed research. What follows is what we've observed and the studies behind the rationale. This is real-world evidence — observational, uncontrolled, and largely self-reported. No statement here is a disease claim.
Systems
Gastrointestinal The Regular One
Strains: Bifidobacterium animalis ssp. lactis + Bifidobacterium longum
- Pooled GI symptom resolution: 47.3% (334/706)
- IBS: 64.7% (44/68)
- Stomach pain: 61.8% (21/34)
- Frequent diarrhea: 61.1% (33/54)
- Leaky gut: 54.5% (42/77)
- GERD: 54.2% (13/24)
Resolution compounds over timeThe figures above reflect the earliest follow-up window. GI symptom resolution is not a one-time snapshot — in the paired cohort (n=651) it compounds across successive intervals as the formulation is iterated against repeat sequencing, climbing from the ~47% pooled rate at the first interval to over 88% by the end of the course (~20 months).
| Follow-up interval | Pooled GI resolution |
|---|---|
| <6 months (early) | ~47.3% |
| By end of course (~20 months) | >88% |
Read as a single curve: resolution starts near 47% in the first months and climbs past 88% by the end of the course (~20 months) in the GI cohort — the same start-to-landing trajectory, measured at two points along it, not two competing numbers.
Rationale (mechanistic, not measured)Bifidobacterium fermentation of fiber to short-chain fatty acids supports motility and mucosal-barrier integrity.
Study: Martoni CJ, et al. Impact of a probiotic product on bowel habits in functional constipation. J Dig Dis. 2019;20(9):478–487. PMID 31271261. pubmed.ncbi.nlm.nih.gov/31271261
Mood / Neurological The Bright One
Strains: Bifidobacterium animalis ssp. lactis + Lactiplantibacillus plantarum
- Pooled neuro resolution: 49.3% (135/274)
- Depression: 65.0% (26/40)
- Brain fog: 48.5% (47/97)
- Fatigue: 48.5% (66/136)
- Anxiety: 45.2% (47/104)
Rationale (mechanistic, not measured)Gut–brain-axis modulation of tryptophan metabolism and vagal signaling.
Study: Hidalgo-Cantabrana C, et al. Lactiplantibacillus plantarum HEAL9 improves cognition in moderately stressed subjects. Nutrients. 2023;15(15):3466. PMID 37571403. pubmed.ncbi.nlm.nih.gov/37571403
Joint / Musculoskeletal The Mighty One
Strains: Bifidobacterium animalis ssp. lactis + Bifidobacterium bifidum
- Pooled joint resolution: 55.3% (42/76)
- Arthritis: 61.9% (13/21)
- Fibromyalgia: 61.1% (11/18)
- Joint pain: 48.6% (18/37)
Rationale (mechanistic, not measured)Anti-inflammatory rationale matching the observed arthritis/fibromyalgia signal.
Immune The Strong One
Strains: Lactobacillus acidophilus + Bifidobacterium longum
- Chronic inflammation: 64.3% (45/70)
- Immune deficiency: 60.0% (9/15) †small sample; interpret with caution
Rationale (mechanistic, not measured)GALT priming and secretory-IgA support.
Study: Leyer GJ, et al. Probiotic effects on cold and influenza-like symptom incidence in children. Pediatrics. 2009;124(2):e172–179. PMID 19651563. pubmed.ncbi.nlm.nih.gov/19651563
Skin The Clear One
Strains: Lactobacillus salivarius + Bifidobacterium animalis ssp. lactis
- Pooled skin resolution: 36.5% (42/115)
- Psoriasis: 61.1% (11/18)
- Dermatitis: 50.0% (7/14)
- Eczema: 34.2% (13/38)
- Acne: 24.4% (11/45)
Metabolic The Lean One
Strains: Bifidobacterium animalis ssp. lactis + Streptococcus thermophilus
Study: Stenman LK, et al. Probiotic with or without fiber controls body fat mass in overweight adults. EBioMedicine. 2016;13:190–200. PMID 27810310. pubmed.ncbi.nlm.nih.gov/27810310
Focus & Calm The Calm One
Strains: Bifidobacterium animalis ssp. lactis + Limosilactobacillus reuteri
Study: Billeci L, et al. Effects of probiotics on electroencephalography in preschoolers with autism. Autism. 2023;27(3):814–827. PMID 35362336. pubmed.ncbi.nlm.nih.gov/35362336
Women's The Radiant One
Strains: Lactobacillus gasseri + Lactobacillus fermentum
Study: Tomusiak A, et al. Efficacy and safety of a vaginal probiotic product containing L. fermentum + L. gasseri. Drug Des Devel Ther. 2015;9:5345–5354. PMID 26451088. pubmed.ncbi.nlm.nih.gov/26451088
Boosters — Tolerability
These are complaint / tolerability rates, not efficacy. Overall baseline complaint rate: 4.87% (n=18,383).
| Booster | FLORE code | Complaint rate | Target |
|---|---|---|---|
| Clear Skin (botanical) | FLORE-B021 | 4.0% | Skin |
| Digest Ease | FLORE-0015 | 4.3% | GI motility |
| Metabolic Fire | FLORE-0016 | 4.5% | Metabolic |
| Anti-Inflammatory (botanical) | FLORE-B031 | 5.1% | Systemic |
| Defense Plus | FLORE-0017 | 5.5% | Immune |
| Joint Ease | FLORE-0018 | 5.7% | Joint |
| Gut Seal | FLORE-0019 | 5.9% | Barrier |
| Mood Lift | FLORE-0020 | 6.0% | Mood |
| Skin Glow | FLORE-0021 | 6.2% | Skin |
| Stress Shield | FLORE-0022 | 6.3% | Stress |
| Focus Fuel | FLORE-0023 | 6.8% | Cognitive |
| Flora Balance | FLORE-0024 | 9.8% | Vaginal pH |
Methodology
Figures are drawn from a paired real-world cohort (n=651; 1,379 symptom-instances) tracked across ~6.6-month median intervals and followed longitudinally out to 20 months, a tolerability cohort (n=18,383), and a sequencing cohort (n=14,704). Analyses used McNemar's test with Benjamini–Hochberg FDR correction. This is real-world evidence, not a controlled trial.
Peer-Reviewed Publication
Phan J, Calvo DC, Nair D, Jain S, Montagne T, Dietsche S, Blanchard K, Treadwell S, Adams J, Krajmalnik-Brown R. Precision synbiotics increase gut microbiome diversity and improve gastrointestinal symptoms in a pilot open-label study for autism spectrum disorder. mSystems. 2024;9(5):e00503-24. PMID 38661344. doi.org/10.1128/msystems.00503-24
Conducted in collaboration with Arizona State University. A pilot open-label study (not a randomized controlled trial) — we say so plainly.
Foundational References
- Hill C, et al. ISAPP consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–514.
- Sanders ME, et al. Probiotics and prebiotics in intestinal health and disease. Nat Rev Gastroenterol Hepatol. 2019;16(10):605–616.
References
- Martoni CJ, et al. Impact of a probiotic product on bowel habits in functional constipation. J Dig Dis. 2019;20(9):478–487. PMID 31271261. pubmed.ncbi.nlm.nih.gov/31271261
- Hidalgo-Cantabrana C, et al. Lactiplantibacillus plantarum HEAL9 improves cognition in moderately stressed subjects. Nutrients. 2023;15(15):3466. PMID 37571403. pubmed.ncbi.nlm.nih.gov/37571403
- Leyer GJ, et al. Probiotic effects on cold and influenza-like symptom incidence in children. Pediatrics. 2009;124(2):e172–179. PMID 19651563. pubmed.ncbi.nlm.nih.gov/19651563
- Stenman LK, et al. Probiotic with or without fiber controls body fat mass in overweight adults. EBioMedicine. 2016;13:190–200. PMID 27810310. pubmed.ncbi.nlm.nih.gov/27810310
- Billeci L, et al. Effects of probiotics on electroencephalography in preschoolers with autism. Autism. 2023;27(3):814–827. PMID 35362336. pubmed.ncbi.nlm.nih.gov/35362336
- Tomusiak A, et al. Efficacy and safety of a vaginal probiotic product containing L. fermentum + L. gasseri. Drug Des Devel Ther. 2015;9:5345–5354. PMID 26451088. pubmed.ncbi.nlm.nih.gov/26451088
- Hill C, et al. ISAPP consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–514.
- Sanders ME, et al. Probiotics and prebiotics in intestinal health and disease. Nat Rev Gastroenterol Hepatol. 2019;16(10):605–616.
Press & Media
Press & media — for product samples, founder interviews, or clinical data briefings, contact support@flore.com
These statements have not been evaluated by the Food and Drug Administration. Flore products are not intended to diagnose, treat, cure, or prevent any disease.